Galmed Pharmaceuticals (GLMD) News Today → Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (From Priority Gold) (Ad) Free GLMD Stock Alerts $0.38 -0.01 (-2.68%) (As of 01:39 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineStockNews.com Begins Coverage on Galmed Pharmaceuticals (NASDAQ:GLMD)americanbankingnews.com - April 24 at 2:38 AMJanOne (NASDAQ:JAN) and Galmed Pharmaceuticals (NASDAQ:GLMD) Head-To-Head Analysisamericanbankingnews.com - April 19 at 1:16 AMGalmed Pharmaceuticals (NASDAQ:GLMD) Earns Sell Rating from Analysts at StockNews.comamericanbankingnews.com - April 16 at 2:28 AMGalmed Pharmaceuticals (NASDAQ: GLMD)fool.com - April 13 at 11:39 PMWall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for April 2024investorplace.com - April 10 at 6:30 AMGalmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2023prnewswire.com - April 4 at 5:06 PMGalmed Granted European Patent For Use Of Aramchol-Resmetirom To Treat NASH/MASH, Liver Fibrosismarkets.businessinsider.com - March 15 at 1:06 PMGalmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver Fibrosisprnewswire.com - March 15 at 9:00 AMGalmed Pharmaceuticals Ltd (GPH.BE)uk.finance.yahoo.com - February 13 at 4:17 AMGalmed Pharmaceuticals Ltd. (GPH.F)uk.finance.yahoo.com - January 3 at 8:40 AMGalmed Announces a delay in the initiation of its Primary Sclerosing Cholangitis (PSC) Phase 2a Studyfinance.yahoo.com - November 20 at 7:39 PMGalmed Pharmaceuticals Ltd GLMDmorningstar.com - November 4 at 11:44 PMGalmed Announces Allowance of New Patent for Aramchol for the Treatment of Pulmonary and Dermal Fibrosisfinance.yahoo.com - September 26 at 9:29 AMGalmed Pharmaceuticals (GLMD) Price Target Increased by 300.00% to 4.08nasdaq.com - August 3 at 11:33 AMGalmed Pharma Shares Drop 30% After Public Offering Pricesmarketwatch.com - July 14 at 4:18 PMGalmed shares slump on pricing discounted stock and warrants offeringseekingalpha.com - July 14 at 4:18 PMGalmed Pharmaceuticals Announces Pricing of $7 Million Public Offeringfinance.yahoo.com - July 14 at 4:18 PMmarketbeat.com - July 14 at 9:34 AMWhy Is Galmed Pharmaceuticals (GLMD) Stock Moving Today?investorplace.com - July 13 at 10:08 AMmarketbeat.com - July 12 at 12:28 PMmarketbeat.com - July 12 at 12:08 PMmarketbeat.com - July 12 at 12:04 PMGalmed to employ OnKai's disruptive Artificial Intelligence (AI) in its Planned Phase 2a Clinical Trial in PSCfinance.yahoo.com - July 10 at 11:32 AMMadrigal begins process seeking OK for multibillion-dollar — yet elusive — NASH drugbizjournals.com - July 3 at 1:51 PMGalmed Pharmaceuticals Stock (NASDAQ:GLMD), Insider Trading Activitybenzinga.com - June 3 at 11:46 PMGalmed Pharmaceuticals Ltd.: Galmed Pharmaceuticals Reports First Quarter 2023 Financial Results and Recent Developmentsfinanznachrichten.de - June 1 at 11:34 AMRecap: Galmed Pharmaceuticals Q1 Earningsmsn.com - June 1 at 11:34 AMGalmed Pharmaceuticals Reports First Quarter 2023 Financial Results and Recent Developmentsfinance.yahoo.com - June 1 at 11:34 AMWhy Galmed Pharmaceuticals (GLMD) Stock Is Surging Todaythestreet.com - May 17 at 1:26 AMAnalysts Offer Insights on Healthcare Companies: Galmed Pharmaceuticals (GLMD) and Haemonetics (HAE)markets.businessinsider.com - May 11 at 2:39 PMGalmed Announces Initiation of a Clinical Development Program to Evaluate Aramchol meglumine for the Treatment of Primary Sclerosing Cholangitis (PSC)finance.yahoo.com - May 9 at 10:23 AMWhy Is Galmed Pharmaceuticals (GLMD) Stock Up 37% Today?msn.com - May 5 at 9:51 AMGalmed Pharmaceuticals forms a Strategic Partnership with OnKaifinance.yahoo.com - May 4 at 8:34 PMGalmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2022finance.yahoo.com - March 29 at 7:35 PMGLMD Galmed Pharmaceuticals Ltd.seekingalpha.com - February 17 at 8:12 AMGalmed Announces Issuance of New Composition of Matter Patent for Aramchol meglumine Saltfinance.yahoo.com - February 8 at 10:28 AMCan Galmed Pharmaceuticals (NASDAQ:GLMD) Afford To Invest In Growth?finance.yahoo.com - January 6 at 8:30 AMGalmed Pharmaceuticals Shares Up 9.2% on Data From Liver Treatment Aramchol Studymarketwatch.com - January 4 at 5:42 PMGalmed reports results from the Open-Label part of the ARMOR study showing improvements in histology, imaging, and biomarkers with Aramcholfinance.yahoo.com - January 4 at 12:41 PMGalmed Pharmaceuticals Ltd. (NASDAQ: GLMD) Announces Receipt of Extension to Meet the Nasdaq's Minimum Bid Price Requirementfinance.yahoo.com - December 14 at 7:01 PMGalmed Pharmaceuticals (GLMD) Moves to Buy: Rationale Behind the Upgradefinance.yahoo.com - September 14 at 3:16 PMGalmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial Resultsfinance.yahoo.com - August 4 at 1:02 PMGalmed's Aramchol Shows Anti-Fibrotic Effects In Lung Fibrosis Animal Modelfinance.yahoo.com - July 7 at 4:15 PMGalmed: New Data Reinforces Expansion Of Aramchol's Clinical Development To Additional Indicationsnasdaq.com - July 7 at 9:46 AMGalmed Reports Significant Anti-Fibrotic Effects of Aramchol in a Lung Fibrosis Modelfinance.yahoo.com - July 7 at 9:46 AMGalmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notificationfinance.yahoo.com - June 17 at 7:16 PMGalmed Pharmaceuticals (NASDAQ:GLMD), Analyst Ratings, Price Targets, Predictionsbenzinga.com - May 25 at 8:49 AMGalmed Pharmaceuticals shares fall after downgrade by Raymond James analystseekingalpha.com - May 18 at 6:52 PMGalmed updates business and clinical development strategy to better leverage Aramchol's anti-fibrotic effectsfinance.yahoo.com - May 17 at 11:50 AMGalmed Pharmaceuticals Reports First Quarter 2022 Financial Resultsfinance.yahoo.com - May 17 at 11:50 AM Get Galmed Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for GLMD and its competitors with MarketBeat's FREE daily newsletter. Email Address Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (Ad)Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow. Click here for your free guide GLMD Media Mentions By Week GLMD Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GLMD News Sentiment▼-0.330.33▲Average Medical News Sentiment GLMD News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GLMD Articles This Week▼20▲GLMD Articles Average Week Get Galmed Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for GLMD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: PBLA News Today DRMA News Today GRI News Today CMRA News Today INM News Today QLGN News Today LSDI News Today NBSE News Today BPTH News Today CMND News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:GLMD) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsFed launches fourth dollar overhaulStansberry ResearchBetter than Bitcoin? The Biotech Stock with 46,751% PotentialBehind the MarketsJeff Bezos Just Humiliated Elon MuskInvestorPlaceDonald Trump Just Predicted "America's Greatest Defeat"Birch Gold Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galmed Pharmaceuticals Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
